The AstraZeneca vaccine contributed 1 cent to earnings per share for the quarter, with the company expecting to move to “mild profitability” for new vaccine orders as it announced $ 1.05 billion in sales for the period.
The pharmaceutical company, which has said it will not make a profit from the vaccine during the pandemic, this week announced plans to set up a separate unit for vaccines and antibody therapies to focus on its coronavirus efforts.
AstraZeneca stressed that the limited profits from the vaccine in the fourth quarter will offset the costs associated with the antibody cocktail for the prevention and treatment of coronavirus, while maintaining estimates for the year.
Total revenue rose 47% to 9.74 billion euros for the quarter to September, while earnings from core activities stood at $ 1.08 per share.
Analysts expected earnings of $ 1.28 per share and sales of $ 9.4 billion.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
